title: Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
abstract: OBJECTIVE
  To compare the effects of preoperative chemotherapy on liver parenchyma morphology, as well as morbidity and mortality after liver resection for colorectal liver metastases.
  
  
  METHODS
  Prospectively collected data on 173 patients undergoing liver resection for CLM between 1/2003 and 9/2005 was analysed in three groups: A: preoperative oxaliplatin (Ox, n=70); B: other chemotherapeutic agents (OC, n=60); and C: surgery alone without chemotherapy (SA, n=43). Blood transfusion, hospital stay, operative procedure, peak postoperative bilirubin levels, complications and histopathology of the resected liver were compared.
  
  
  RESULTS
  Intra-operative blood transfusion requirement (34%) and biliary complications (16%) was higher in patients receiving oxaliplatin-based chemotherapy (p=0.01 and p=0.06, respectively). Oxaliplatin-based chemotherapy was also associated with sinusoidal dilatation of mild grade in 52.8% vs. 26.6% and 23.3% patients (p=0.007 and p=0.004) in other groups, respectively. Steatosis was similarly distributed across the study group. Postoperative mortality was 2, 1 and 4 patients, respectively (p=ns).
  
  
  CONCLUSIONS
  Oxaliplatin-based preoperative chemotherapy is associated with vascular alterations in the liver parenchyma without significantly increasing the risk of steatosis, or postoperative morbidity and mortality.
authors.affiliation: Hepato-biliary-pancreatic Surgery and Liver Transplant Unit, Nuffield House, Queen Elizabeth Hospital, Edgbaston, Birmingham B152TH, UK.
authors.forename: N N
authors.initials: NN
authors.lastname: Mehta
authors.forename: R
authors.initials: R
authors.lastname: Ravikumar
authors.forename: C A
authors.initials: CA
authors.lastname: Coldham
authors.forename: J A C
authors.initials: JA
authors.lastname: Buckels
authors.forename: S G
authors.initials: SG
authors.lastname: Hubscher
authors.forename: S R
authors.initials: SR
authors.lastname: Bramhall
authors.forename: S J
authors.initials: SJ
authors.lastname: Wigmore
authors.forename: A D
authors.initials: AD
authors.lastname: Mayer
authors.forename: D F
authors.initials: DF
authors.lastname: Mirza
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000473:pathology*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006498:Hepatectomy / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077150:Oxaliplatin; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin